RecruitingNot ApplicableNCT06061874

Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

Ga68-labeled Fibroblast Activation Protein Inhibitor-46 (Ga68-FAPI-46) PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

Sponsor

Jules Bordet Institute

Enrollment

80 participants

Start Date

May 30, 2023

Study Type

INTERVENTIONAL

Conditions

Cancer Peritoneal Carcinomatosis

Summary

This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein). The aim of the study is to assess the accuracy of Ga68-FAPI-46 PET/CT for preoperative assessment of peritoneal carcinomatosis in colorectal and ovarian cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is using a special PET/CT scan (Ga68-FAPI-46) to detect cancer that has spread to the lining of the abdominal cavity (peritoneal metastases) in colorectal and ovarian cancer patients, to see if this scan helps surgeons better plan complete removal of peritoneal disease. **You may be eligible if...** - You have confirmed colorectal or ovarian cancer - You have known or suspected spread to the peritoneum (abdominal lining) - You are scheduled for surgery with the intent to completely remove the peritoneal disease - Your general health is adequate (ECOG score 0-2) **You may NOT be eligible if...** - Your cancer has spread beyond the abdomen in a way that makes surgery impossible - You are pregnant or breastfeeding - Recent prior PET/CT scans would interfere with interpretation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.